Background Transplantation offers the best survival for patients with end stage organ disease. Transplant of hepatitis C virus (HCV) nucleic acid test (NAT) positive organs into negative recipients is a novel strategy that can expand the donor pool. We aim to evaluate our centre’s experience. Methods We preformed a retrospective review of anti-HCV NAT positive and negative organs into negative recipients transplanted over 27 months. Primary outcome was the success rate of eradication of HCV post-transplant. Secondary outcomes were rate of transmission of HCV, treatment adverse events, and graft failure. Results 33 anti-HCV positive organs were transplanted into negative recipients. 22 (66.7%) were NAT positive. Median recipients age was 49 years (interquartile range [IQR] 44.5–62.0) with the majority being males (57.6%). NAT positive organ transplantations included 16 kidneys, 3 livers, 1 kidney-pancreas, 1 liver-kidney, and 1 heart. The most common HCV genotype was 1a (59.1%). The median time to initiating therapy was 41.5 days. SVR12 was 100% in patients who finished therapy. There were no adverse events with therapy and no graft failure. Conclusions Anti-HCV NAT positive organ transplantation into negative recipients is safe with excellent eradication rates and no significant adverse events or graft failure. This would expand donor pool to close the gap between supply and demand.

No abstract

No abstract

(1) Background: Adolescents-and-young-adults (AYA) are prone to anxiety. This study assessed AYA’s level of anxiety during the COVID-19 pandemic; and determined if anxiety levels were associated with country-income and region, socio-demographic profile and medical history of individuals. (2) Methods: A survey collected data from participants in 25 countries. Dependent-variables included general-anxiety level, and independent-variables included medical problems, COVID-19 infection, age, sex, education, and country-income-level and region. A multilevel-multinomial-logistic regression analysis was conducted to determine the association between dependent, and independent-variables. (3) Results: Of the 6989 respondents, 2964 (42.4%) had normal-anxiety, and 2621 (37.5%), 900 (12.9%) and 504 (7.2%) had mild, moderate and severe-anxiety, respectively. Participants from the African region (AFR) had lower odds of mild, moderate and severe than normal-anxiety compared to those from the Eastern-Mediterranean-region (EMR). Also, participants from lower-middle-income-countries (LMICs) had higher odds of mild and moderate than normal-anxiety compared to those from low-income-countries (LICs). Females, older-adolescents, with medical-problems, suspected-but-not-tested-for-COVID-19, and those with friends/family-infected with COVID-19 had significantly greater odds of different anxiety-levels. (4) Conclusions: One-in-five AYA had moderate to severe-anxiety during the COVID-19-pandemic. There were differences in anxiety-levels among AYAs by region and income-level, emphasizing the need for targeted public health interventions based on nationally-identified priorities.

BackgroundHelicobacter pylori (HP) is a common bacterium that globally infects humans. The significance of HP infection and eradication of kidney impairment remain ambiguous. Moreover, little is known about whether elimination of the bacteria has any consequence on kidney function. This study aimed to explore the relationship between HP eradication and kidney function in patients with chronic gastritis (CG). MethodologyWe retrospectively reviewed the records of all CG patients with eradicated HP at King Abdulaziz University Hospital between June 2002 and June 2021. All patients older than 18 years, diagnosed with CG in whom HP had been eradicated, were included. Out of 1,936 patients' records, only 46 met the criteria. ResultsThe mean age of the study sample was 48 years; in addition, 58.7% of the patients were obese. There was no significant difference in serum creatinine, blood urea nitrogen, and glomerular filtration rate after HP eradication (P-values of 0.414, 0.112, and 0.300, respectively). ConclusionsWe found no relationship between the eradication of HP and improvement in renal function. However, prospective population-based studies must be conducted to assess an association between HP eradication and renal function, as well the future risk of nephropathy with the persistence of HP. As such, we recommend a multicenter study that includes a representative sample size.

Background The sequelae of decompensated cirrhosis include a reduction in both hepatic coagulation factors and platelets. While historically it was felt that patients with cirrhosis were naturally anticoagulated, recent studies have refuted this. As a result, cirrhotic patients may be a risk for development of venous thromboembolism (VTE). Conflicting data regarding VTE risks limits guidance for clinicians. Aims National Inpatient Sample (NIS) data were analyzed to compare the prevalence of VTE among hospitalized patients with and without cirrhosis. Methods NIS is a database of US inpatient admissions. The 2014 NIS database was interrogated using ICD-9-CM codes to identify adult patients with cirrhosis and VTE. Baseline characteristics for patients with and without cirrhosis were compared. Multivariate regression models identified risks of VTE adjusting for survey procedures. Data were presented with odds ratio (OR) with 95% confidence intervals (95% CI). A p-value <0.05 was statistically significant. Results 605,825 patients with cirrhosis were included. VTE occurred in 8,940 patients with cirrhosis and 627,490 controls (1.5% and 2.2% respectively). The corresponding values for PE were 0.5% and 1.1%; and for DVT were 1.1% and 1.4%. The OR for VTE in patients with cirrhosis was 0.547 [95% CI (0.520–0.576), p <0.001] when adjusting for risk factors for VTE (table 1). Conclusions Prevalence of VTE was lower among inpatients with cirrhosis compared to controls. Use of anticoagulation was not controlled as these data were not available, which could limit some associations. Further prospective studies are needed to overcome the limitations of retrospective analysis. Funding Agencies None

No abstract

No abstract